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Abstract Dosing guidelines for patients with type 1 diabetes
using continuous subcutaneous insulin infusion (CSII), which
are historically based on clinical experience and retrospective
studies of patients consuming anAmerican diet, recommend that
basal insulin should represent approximately 50 % of the total
daily dose (TDD). Recent prospective studies in the USA and
Japan conclude that the more appropriate proportion is closer to
30–40 % of TDD. In addition, currently used formulas for cal-
culating the carbohydrate-to-insulin ratio (CIR) and correction
factor (CF) may lead to underdosing of bolus insulin by as much
as 12.8–50 % for a hypothetical patient. The discrepancies be-
tween traditional formulas and data from newer studies can be
accounted for by the more rigorous design of the newer studies
(e.g., prospective design, controlled diets, meal omission, and
frequent glucose monitoring). International differences in diet
compositionmay also be important to consider when developing
dosing recommendations for CSII.
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Introduction
Continuous subcutaneous insulin infusion (CSII) is an intensive
therapy typically reserved for motivated patients with type 1
diabetes (T1D) who have frequent hypoglycemia, a significant
dawn phenomenon (excess hepatic glucose production and non-
hepatic insulin resistance in the morning period) or widely fluc-
tuating blood glucose when using multiple daily injections
(MDIs) [1•]. If properly managed, CSII may provide patients
with improved glucose control compared with MDI therapy [2,
3] and a lower incidence of severe hypoglycemia [4]. As noted
in a recent review, the total number of insulin pump users world-
wide is unknown but believed to vary greatly across countries
[5]. Estimates suggest that there may be as many as 350,000–
515,000 insulin pump users in the USA [1•, 6]. A large registry-
based study of the more experienced endocrinology centers in
the USA indicated that as many as 50 % of their patients with
T1D used a pump [7]. Among European nations, in a 2010
report, the proportion of patients with T1D using CSII varies
substantially, from ∼1 % in Russia and Portugal to about 20 %
in Norway, Austria, the Netherlands, and Switzerland [8]. A
2011 publication estimated that about 10 % of Australian pa-
tients were using CSII, with an increasing number of patients
initiating CSII sooner after diagnosis than in previous years [9].
Among Asian nations, the proportion of patients with T1D who
are using CSII in Japan is estimated to be 7 % (author commu-
nication with Medtronic Japan).
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Precise insulin dosing during CSII is necessary to enable
patients with diabetes to adhere to current treatment guidelines
[10, 11]. Unfortunately, precise dosing is complicated by the
need to calculate two to five different basal rates for a 24-h
period to match varying insulin needs over the day [12, 13].
Accurate formulas are essential to estimate the initial insulin
dose and to adjust insulin pump settings, and these include the
total basal dose (TBD), carbohydrate-to-insulin ratio (CIR),
and the correction factor (CF; see Table 1). Patients using
CSII have insulin requirements that are specific to each indi-
vidual, and most patients do not have the ability to slowly
titrate their insulin up to a safe and effective dose. Over the
last decade, rigorously designed studies have been completed
that question the accepted methods for insulin-dosing calcu-
lation used worldwide. We will discuss this discrepancy and
its impact on treating T1D with CSII.
Where Have Current Dosing Formulas Come From?
The chronological development of published insulin-dosing
formulas is presented in Table 2, with a detailed description
of their derivation available in a recent review [29•]. Briefly,
the first formula proposed in 1922, using a very crude insulin
preparation, was weight based and was calculated conserva-
tively in order to avoid hypoglycemia and to preserve the
limited amount of insulin available (body weight × insulin
sensitivity in dogs [U/kg], divided by 2) [30]. In 1982,
Skyler et al., based upon clinical experience using buffered
human regular insulin, suggested that the TBD should be
about 40 % of the total daily dose (TDD) [15].
The next set of formulas, which form the basis for widely
used guidelines, were derived from retrospective insulin pump
downloads. In 1998, according to Davidson et al. [16], Steed
proposed the “rule of 3” for estimating CIR (CIR=[3×weight
in lb]/TDD). Current formulas for deriving CF can be traced to
the suggestion by Davidson et al. of the “1500 rule” for
calculating CF (CF= 1500/TDD), later revised to “1700”
(CF=1700/TDD) [16]. Together, these three formulas became
the foundation of the Accurate Insulin Management (AIM) sys-
tem. Walsh et al., also using retrospective pump download in-
formation, further suggested that CIR be calculated from 450/
TDD [18]. Since the previous formulas had been based on reg-
ular insulin used in pump treatment, Walsh et al. recommended
that they be modified to CF=2000/TDD and essentially agreed
with Davidson that the formula used to estimate CIR should be
CIR=(2.6×weight in lb)/TDD, reflecting the widespread use of
rapid-acting insulin analogs [18]. Based on these early studies,
current insulin-dosing guidelines in theAmericanAssociation of
Clinical Endocrinologists/American College of Endocrinology
(AACE/ACE) consensus statement for the USA [1•] recom-
mend the following formulas: TBD (U) = 50 % of TDD,
CIR=450/TDD, and CF=1700/TDD.
A few years ago, researchers working independently in Japan
and the USA published studies using more rigorous designs and
suggested that traditional formulas overestimated basal insulin
requirements and underestimated bolus requirements (reviewed
in [29•]). Key features of these prospective studies included
isocaloric controlled diets, meal omission to study basal rate,
timed blood glucose or continuous glucose monitoring
(CGM)-guided dose titration, and omission of those individuals
with insulin sensitivity that significantly deviated from normal.
A strength of the US studies was that CGM allowed for preci-
sion in glucose measurement that was unobtainable with inter-
mittent self-monitored blood glucose tests and was able to cap-
ture nocturnal and post-meal variations in blood glucose [12,
22]. These data are further supported by a post hoc analysis
including patients from two other studies who met the original
inclusion criteria [31], resulting in a total of 101 patients [25]. In
that analysis, TBD was estimated as 40 % of TDD.
Studies by Kuroda et al. in Osaka and Tokushima, and by
Nakamura et al. in Kobe, Japan, suggest that King’s US results
may be generalizable to other populations. In the first of these
studies by Kuroda et al., TBD was determined to be
Table 1 Definition of parameters
used in formulas for establishing
proper daily insulin dose in CSII
Parameter Definition
TDD The total of basal and bolus insulin dosage in U/day
TBD The fraction of TDD given as basal insulin in U/day
CIR A number that, when divided into the number of grams of carbohydrates to be consumed, yields the
units of insulin needed to lower blood glucose to a pre-meal level within 2–4 h. CIR is usually
between 5 and 20 g of carbohydrates/U
CF A number that, when divided into the difference between actual and target blood glucose, indicates
the number of extra units of insulin necessary to bring glucose within target range, within 2–4 h.
CF is usually between 20 and 100 mg/dL/U
Source: [14]
Patients with greater insulin sensitivity will have higher CFs and CIRs
CF correction factor,CIR carbohydrate-to-insulin ratio,CSII continuous subcutaneous insulin infusion, TBD total
basal dose, TDD total daily dose
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approximately 30% of TDD [23]. In their second study, Kuroda
et al. established patients’ basal dose and then assessed CIR,
finding that CIR exhibited diurnal variability ranging from
300/TDD at breakfast to 400/TDD for lunch or dinner [24]. In
another prospective study, Nakamura et al. studied 28 Japanese
adults with pump-treated T1D at Kobe University, Japan [28•].
After stabilizing subjects on an isocaloric, fixed diet (50–60 %
carbohydrate/20–25 % fat/15–20 % protein), the basal dose was
adjusted to 130±30 mg/dL with meal omission and 8-point
blood glucose testing. After the basal dose was established, the
CIR was established to achieve a postprandial glucose (∼2 h) of
<180 mg/dL. Their results indicated that the TBD/TDD should
be 27.3 % and the CIR for breakfast should be 300/TDD.
When these prospective studies are combined, the TBD/
TDD appears to be much lower than the current recommen-
dation of 50 % and somewhat closer to 30 % (see Table 2).
The slightly lower basal dose in the Japanese compared to the
US studies may be due to higher-carbohydrate and lower-fat
proportions in the Japanese diet. Since most worldwide stud-
ies suggest the TDD/kg is around 0.5–0.6 U/kg, the lower
basal dose would lead to a higher meal bolus (a lower CIR).
Although both Japanese studies recommend a lower CIR in
the morning and a higher CIR during the day, all studies con-
firm that higher bolus doses are necessary.
Explaining the Discrepancies
Study design issues may help to explain the discrepancy be-
tween the results of the King, Kuroda, and Nakamura studies
vs. those of earlier work. A major distinction is that these
newer results are based on prospective data [12, 13, 22, 23,
25, 28•], whereas the current guidelines are derived from ret-
rospective studies that did not exclude patients who may have
experienced transient changes in insulin resistance, for exam-
ple, due to illness, surgery, or prednisone treatment [16–18].
In the retrospective studies, downloaded pump data were not
accompanied by information about patients’ diet, snacks,
physical activity, the timing and intensity of their blood glu-
cose monitoring, or post-meal glucose targets, while the pro-
spective studies used controlled diets, self-monitored blood
glucose or CGM, and/or frequent clinic visits [12, 13, 22,
23, 25]. The prospective studies also determined patients’
basal rate using sequential meal omissions and their CIR by
prescribing meals of known carbohydrate content. CF was
determined either by reducing the meal bolus and determining
the insulin dose needed to achieve target glucose within 2–4 h,
or by clinical judgment.
It should be noted that the CIR and CF values in the studies
by Davidson et al. [16, 17] were determined without knowing
the proportion of patients who used their bolus calculators and
without the ability to confirm whether the pump recommen-
dations were actually followed, and that a linear regression
was used for data that may not have met criteria for normality.
In Davidson et al., patients’ mean TDD was determined from
only 7 days of data [16]. It is important to recognize that
patient self-monitoring is a less than ideal way to assess blood
glucose over an entire 24-h period; it may not capture noctur-
nal variations and intermittent, single-point estimates cannot
reflect the full variation throughout post-meal periods.
Table 2 Evolution of dosing formulas for insulin therapy
Study TBD CIR CF
Clinical Skyler et al. 1982 [15] ∼40 % TDD
Davidson 1982 (see Davidson et al. 2008) [16] 1500/TDD
Steed 1998 (cited in Davidson et al. 2008) [16] (3 ×wt lb)/TDD
Retrospective Davidson et al. 2003 [17] 48 %×TDD (2.8 ×wt lb)/TDD 1724/TDD
Davidson et al. 2008 [16] 47 %×TDD 441/TDDa or (2.8 ×wt lb)/TDD 1694/TDD
Walsh et al. 2010 [18] 47.6 %×TDD (2.6 ×wt lb)/TDD 1960/TDD
Alcantara-Aragon et al. 2015 [19•] 58 %×TDD 350–400/TDD NR
Pankowska et al. 2008 (pediatric) [20] 27.7 %×TDD NR NR
Alemzadeh et al. 2012 (pediatric) [21] 28 %×TDD 13.5 ×BW kg/TDD 2800/TDD
Prospective King and Armstrong 2007a,b [12, 22] 38.4 %×TDD (217/TDD)+ 3 (1076/TDD)+ 12
Kuroda et al. 2011 [23] 27.7 × TDD NR NR
Kuroda et al. 2012 [24] 27.0 × TDD 300–400/TDD NR
King 2010 [25] 40 %×TDD 300/TDD 1500/TDD
King et al. 2012a [26] 33 %×TDD 90/TBD NR
King et al. 2012c [27] 33.9 %×TDD 365/TDD
Nakamura et al. 2014 [28•] 27.3 %×TDD 300–500/TDD
CF correction factor, CIR carbohydrate-to-insulin ratio, NR not reported, TBD total basal dose, TDD total daily dose
a For calculation of TDD, patients with type 2 diabetes were excluded
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As was the case with the studies by Davidson et al., it is not
knownwhether the pump settings in the studies byWalsh et al.
were made based on a standardized diet, whether basal rates
were set by studying glucose during meal omissions, whether
frequent and timed blood glucose readings were performed, or
whether patients with transient changes in insulin sensitivity
were excluded. And, although Walsh et al. identified
Davidson et al.’s studies as single center, they did not identify
their own patient distribution [18].
The ratio of ∼50 % for TBD/TDD used in current formulas
is comparable to that reported in clinical trials of basal–bolus
therapy in T1D [e.g., 32]. This is not surprising, given that
morning fasting plasma glucose is often used as a surrogate
for basal insulin needs for the remainder of the day. Titrating
to morning fasting glucose may not be the optimum way to
determine basal dose, as factors other than inadequate basal
insulin (e.g., the “dawn phenomenon,” late-night eating, de-
layed gastric emptying, and increased hepatic glucose output
due to fatty infiltration) may elevate plasma glucose when
measured pre-breakfast [14, 28, 33•].
It is also possible that, in the retrospective studies utilizing
CSII, post-meal hypoglycemia attributed to excessive bolus
dosing may actually have been due to excessive basal dosing.
In CSII, basal doses may seem somewhat easier and safer to
increase than a bolus dose. In addition, since CGM was not
used, nocturnal hypoglycemia arising from excessive basal
dosing may not have been recognized. Both of the Kuroda
et al. studies used 7–8-point blood glucose measurements
rather than CGM and, as a result, may not have captured all
post-meal or nocturnal blood glucose variations. As has been
noted, it is also unknown whether the single ethnic group in
the Kuroda et al. studies and/or the Japanese diet, which con-
tains less fat and more carbohydrates than western diets, may
also have affected these results [23, 24, 28•].
Internationalizing These Findings—Should Dietary
Patterns Matter?
The dosing guidelines in CSII in India [34] and China [35]
recommend the same dosing formulas as AACE/ACE, i.e.,
TBD=50 % of TDD and CIR=450/TDD. This seems ques-
tionable because the diet composition in these nations is mark-
edly different from the US diet that was probably consumed in
the Davidson andWalsh studies. The American diet is approx-
imately 49 % carbohydrate and 38 % fat, compared to 61%
and 27 %, respectively, in China, and 71% and 19 %, respec-
tively, in India [36].
How might dietary carbohydrate differences affect
dosing formulas across different cultures? The denomi-
nator for the TBD formula, TDD, is the summation of
the TBD and total bolus dose. Increasing the dietary
carbohydrates would increase the total bolus dose,
increasing the TDD but not the TBD, resulting in lower
recommendations for the TBD/TDD ratio. For example,
every 10 % increase in dietary carbohydrates and as-
suming 1800-calorie diet, CIR = 10 g/U, no corrective
boluses, and a TBD= 10 U, there would be a 10 %
decrease in the TBD/TDD ratio.
Given that a high-fat, low-carbohydrate intake reduces the
ability of basal insulin to suppress hepatic glucose production
[37], it could be assumed that the US recommendations for
basal dose would be higher than in countries with lower-fat
content in their diet. For the Asian Indian diet, for example,
consisting of 71 % carbohydrates and 19 % fat, the total bolus
dose should be much higher than the US diet, but the total
basal dose would be less. When considering the combined
effects of increased dietary carbohydrates, reduced fat, and
the possible excessively high recommendations based on ret-
rospective studies, the recommendation of TBD to be 50 % of
TDD seems excessive for India, China, and other countries of
similar diet composition. The TBD/TDD ratio of <30 % in the
Japanese studies supports this contention [23, 24, 28•].
How Have Existing Guidelines Embraced This New
Information?
Very little new empirical research focusing on insulin dosing
in CSII in T1D has been published since the King and Kuroda
studies described earlier [i.e., 12, 22–25]. Nevertheless, one
retrospective study of 170 pump-treated patients with T1D
from Spain that focused on establishing the CIR found that
the mean CIR in the morning was 350/TDD for breakfast and
400/TDD for other meals [19•]. The TBD/TDD reported in
that study was quite high, 58 %, and it was not stated whether
the TBD had been set by standardized diet, intense glucose
monitoring, and meal omissions.
There have been several papers about insulin dosing
in type 2 diabetes (T2D) [38–41]. In China, in a study
with 65 newly diagnosed patients with T2D treated with
an insulin pump, TBD was about 40 % of TDD [40],
whereas, in another study comparing MDI and CSII
(100 patients in each group), TBD was 50.9 % in the
MDI group vs. 69.1 % in the CSII group [40].
Interestingly, the actual TBD/TDD ratio in patients
using MDI basal–bolus therapy was about 20 % in an-
other uncontrolled study [38]. C-peptide represents the
residual insulin secretion, and it is not usually depleted
in patients with type 2 diabetes. Pankowska et al. com-
pared the basal insulin requirement in C-peptide-positive
and C-peptide-negative patients with type 1 diabetes
[20]. TBD/TDD ratio was 0.32 in C-peptide-negative
patients and 0.23 in C-peptide-positive patients. Insulin
secretion might reduce the basal insulin requirement. So,
the TBD/TDD in patients with type 2 diabetes might be
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lower than TBD/TDD in patients with type 1 diabetes.
More vigorous studies [e.g., 27] should answer this
question.
What Should Be Done in High-Quality Studies
to Further Encourage Adoption of These Revised
Formulas—What Else Is Needed?
Accurate formulas are essential to estimate the initial insulin
dose and to adjust insulin pump settings. For formulas to be
accepted, we believe that they should be based on studies with
the following attributes:
1. An adequate number of representative patients.
2. Excluding patients who have altered insulin sensitivity,
such as those with renal failure or on corticoid therapy.
3. Diet of known composition that reflects that of the country
in which the recommendations are targeted. The fat
(increased insulin resistance and delayed gastric emptying)
and protein content (gluconeogenesis and increase glucagon)
have a significant effect on the estimation of dosing factors
[33•, 42, 43, 44•].
4. Meals omitted at various times to isolate and adjust the
basal insulin dose first.
5. After the basal dose has reached goal, determine the CIR
by the amount of insulin necessary to return the post-meal
glucose to target following a meal of known carbohydrate
content.
6. The plasma glucose must be monitored by focused timed
and frequent self-monitored blood glucose or, ideally,
CGM.
7. The expected variability of a formula result should be
stated to allow the provider to judge the appropriateness
of a calculated dosing parameter.
Moving Forward
Data from several modestly sized but carefully controlled pro-
spective trials in Japanese and American populations suggest
that current widely used insulin-dosing recommendations
should be reconsidered, because existing formulas are likely
to result in an excess basal insulin dose and an insufficient
bolus dose. We recommend a revised set of formulas to esti-
mate dosing for insulin pump-treated patients with T1D. For
example, for a hypothetical patient with a TDD of 50 U con-
suming a 70-g carbohydrate meal, under existing formulas
(TBD (U)=50 % of TDD, CIR=450/TDD, CF=1700/TDD
[1•]), the bolus dose would be ∼7.8 U and the TBD would be
∼25 U. Using the revised formula (TBD=30–40 % TDD and
CIR=300–400/TDD) results in a bolus dose of 8.8–11.7 U
and a TBD of 15–20 U. This difference amounts to anywhere
from a 12.8–50 % increase in prandial bolus dose and a 20–
40 % decrease in TBD.
It remains to be seen whether the estimated range for
the CIR (i.e., 300–400) can be further narrowed and
whether the diurnal variability of CIR should be taken
into account. It has been reported that higher insulin bo-
luses are needed for the first meal of the day [24, 28•, 45],
while others still have not found this to be the case. King
et al. found that suppression of the earlier-than-breakfast
hepatic glucose production mitigated the increased need
for higher insulin doses during that time period [12, 22].
Hinshaw et al. determined, through extensive testing, that,
while there may be an increase in insulin resistance in the
morning, the marked within-subject variability obliterated
any statistical difference [46]. More studies using inten-
sive glucose monitoring (such as CGM) for full suppres-
sion of the dawn phenomenon are needed to determine
whether there is any significant change in bolus-dosing
factors associated with the meals of the day.
There has only been one reported study of the direct assess-
ment of CF. King and Armstrong [22] gave only 75 % of the
predicted bolus for a meal. After 4 h post-meal, the resulting
hyperglycemia was treated by a bolus of insulin adjusted to
return the interstitial glucose to within 20 % of a target of
100 mg/dL within 4 h. They found that, when the slope of
the relationship between CF and the 1/TDD is forced through
zero, the CF-estimating formula would be 1407/TDD
(R2 = 0.620). The ratio CF/CIR was 4.44 (R2 = 0.900). This
tight relationship exceeded that of deriving the CF from
1/TDD, suggesting that, if CIR is correctly determined,
4.44×CIR would be a better estimate then the rounded rela-
tionship of 1400/TDD. A greater bolus to treat episodic hy-
perglycemia is in keeping with the greater bolus for meal
carbohydrates. However, more studies are required to support
these findings.
We have also shown that the revised formulas can in-
form insulin dosing in patients with T1D using MDI ther-
apy [13, 26]. It is important to note that with once-nightly
injection of a basal insulin analog, one cannot obtain a flat
baseline glucose level during the dawn phenomenon peri-
od without increasing the risk for hypoglycemia during
the non-dawn periods [13, 26, 47]. On the other hand,
in pump-treated T2D when vigorously studied with diet
control and CGM titration, one basal rate was successful
in achieving nearly ideal basal control, 99 mg/dL, in 80 %
of patients [27]. The TBD was only 0.22 U/kg. With re-
spect to once-daily basal insulin injection regimens in
T2D, in 11 treat-to-target clinical trials with neutral prot-
amine Hagedorn (NPH) insulin or insulin glargine, main-
taining a mean morning fasting glucose of <110 mg/dL
required an average basal insulin dose of >0.6 U/kg
[48•]—a dose nearly three times greater than that
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suggested using our revised formula (∼0.2 U/kg). Again,
such disparities have enormous clinical implications for
patients. As the revised formulas are based on research
in T1D patients only, broad applicability for T2D patients
is unknown. However, there may be some utility in guid-
ing clinicians when initiating or intensifying basal–bolus
insulin therapy in these patients as well, paying close
attention to individual patient factors such as residual
beta-cell function and degree of insulin resistance.
Clearly, comparative studies of different formulas are
needed in these patients as well.
Conclusions
Further studies are warranted to explore insulin dosing in
patients with diabetes, during which meals are controlled
and glucose intensely monitored. Ideally, these should be
prospective and designed to allow head-to-head compari-
son of different dosing formulas. This would also provide
important information about differences in hypoglycemia
or hyperglycemia with different dosing formulas. Finally,
regardless of which formulas are used, it is important to
emphasize that recommended insulin-dosing formulas are
intended as estimates, and should always be tempered
with clinical judgment, based upon experience, according
to patient-specific factors including diurnal variation in
blood glucose and activity level. For example, it is possi-
ble that some patients might require more than one CIR
over a 24-h period to achieve optimal glycemic control
and prevent nocturnal hypoglycemia. Until appropriate
studies are published, we believe that new evidence indi-
cates that the following revised formula should be consid-
ered as a starting point when initiating a patient with T1D
on intensive therapy: TBD = 30–40 % of TDD and
CIR= 300–400/TDD.
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